San Francisco-based Ideaya Biosciences on Tuesday said that it has dosed its first uveal melanoma patient in a clinical trial evaluating its PKC inhibitor IDE196 with Pfizer’s cMET inhibitor crizotinib (Xalkori).
Archive | Clinical Trials
Ideaya Biosciences Begins Trial of IDE196, Xalkori in Uveal Melanoma Patients
Posted in Melanoma News, Health Professionals, Clinical Trials
Philogen Announces the Completion of a Second Interim Analysis of Its Phase III Clinical Program With Nidlegy for the Treatment of Melanoma
Philogen S.p.A., a clinical-stage biotechnology company focused on antibody-based therapeutics, is pleased to announce that 50% of the expected events for the primary outcome analysis of the PIVOTAL study were reached in December 2020.
Posted in Melanoma News, Health Professionals, Clinical Trials
World first melanoma success in Australia prompts new trial
A Sydney man who was seriously ill with advanced melanoma has made a remarkable recovery after receiving a drug reserved for breast and ovarian cancer.
Posted in Melanoma News, Health Professionals, Patients, Clinical Trials, Latest News
Sydney man recovers from advanced melanoma in unconventional treatment
A Sydney man has recovered from advanced melanoma thanks to a drug usually used for breast and ovarian cancer, prompting the Melanoma Institute to run a new clinical trial.
Posted in Melanoma News, Health Professionals, Patients, Clinical Trials, Latest News
